The Impact of COVID-19 on Clinical Trials: Where are We? And Where are We Going?

The Impact of COVID-19 on Clinical Trials: Where are We? And Where are We Going?

By Aaron Fleishman, Director, Market Development on Tue, Jun 23, 2020 | 2 min read

 

COVID podcast_sponsored by BBK

Get the latest insights from our BBK-sponsored podcast.

As the country goes through the phases of reopening, what does that mean for the patient and site experience in clinical trials? PharmaTalkRadio’s Valerie Bowling discusses the future of clinical trials with Ray Dorsey, MD, Matt Kibby, and Craig Lipset in this feature podcast.

The industry thought leaders share their perspectives on the rapid adoption of virtual solutions and discuss the potential impact on future clinical trial participation and study design. In addition, they explore the possibility of hybrid trials becoming the new normal, and offer advice for how clinical trial sponsors can position themselves for success.

 

CLICK HERE to listen to the podcast.

 

Participants: 

Ray Dorsey, MD, David M. Levy Professor of Neurology and Director of the Center for Health & Technology at the University of Rochester 

Matt Kibby, President, Principal, BBK Worldwide 

Craig Lipset, Founder of Clinical Innovation Partners and the former Head of Clinical Innovation and Venture Partner at Pfizer

 

Topics: Clinical Trials, Pharma15 Live!, COVID-19, Matt Kibby, Craig Lipset, Decentralized Trials, Conference Forum